News
BMS commits $40B for US expansion, Shionogi buys Torii Pharma for $1.05B, Bavarian Nordic extends BARDA deal, multiple ...
Vor Bio, founded by famed cancer biologist Siddhartha Mukherjee, is looking for a way out. Its decision to pursue strategic ...
'Find a way, or make one': How two scientists hope to revitalize CRISPR's rare disease crisis
Fyodor Urnov and Kiran Musunuru advocate for streamlined CRISPR treatments for rare genetic diseases, partnering with Danaher ...
After working off $20 million in seed funding for about four years, HAYA Therapeutics tapped the funding well and came back ...
Teva is planning to reduce its headcount by 8% by 2027, the company announced on Wednesday, as it enters the next phase of ...
Gilead is the latest drugmaker to announce that it’s pouring billions of dollars into its manufacturing and R&D operations in ...
The FDA announced a two-day meeting of its Oncologic Drugs Advisory Committee (ODAC) later this month to review cancer drugs ...
Vinay Prasad named to replace Peter Marks as head of FDA's Center for Biologics Evaluation and Research; discussion planned ...
A federal court handed the FDA and Eli Lilly a major win in a case challenging the end of the tirzepatide shortage.
Charles River Laboratories is set to start a strategic review and add four new board members after it settled on a ...
President Trump met with pharma CEOs at the White House. After praising investments, a 'most favored nation' drug pricing ...
CRISPR Therapeutics has revealed promising but early data from its first clinical study of a gene editing therapy to lower ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results